Three-year survival in patients with cT4N0 breast cancer after neoadjuvant systemic therapy according to the extent of axillary surgery
Abstract
Purpose. To compare 3-year survival outcomes in patients with cT4N0M0 breast cancer who achieved ycN0 status after neoadjuvant systemic therapy (NAST), according to the extent of axillary surgery. Materials and Methods. This single-center, prospective, nonrandomized cohort study included a historical control group. Patients were stratified into three groups according to the extent of axillary surgery: ALND, SLNB alone, and SLNB with completion ALND (patients with metastases in sentinel lymph node who underwent completion ALND). Three-year locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Results. The study included 274 patients with cT4N0M0 breast cancer: the ALND group (n=110), the SLNB group (n=145), and the SLNB with completion ALND group (n=19). Median follow-up was 40.9 months (QR 32.1–53.2). The ALND and SLNB groups were comparable in age, histologic type, tumor grade, molecular subtype, and pathologic response. Locoregional recurrence occurred in 2.7% of patients in the ALND group and 2.8% in the SLNB group (p>0.999); distant metastases occurred in 10.9% and 9.0% (p=0.664); and death occurred in 11.8% and 5.5% (p=0.106), respectively. Three-year LRRFS was 98.0% (95% CI 95.2–100%) in the ALND group versus 96.9% (95% CI 93.4–100%) in the SLNB group (p=0.84); DFS was 91.6% (95% CI 86.2–97.4%) versus 90.7% (95% CI 85.4– 96.4%) (p=0.92); and OS was 92.6% (95% CI 87.4–98.0%) versus 97.2% (95% CI 94.1–100%) (p=0.82). No statistically significant differences were observed between groups for any survival endpoint. Conclusion . In patients with cT4N0M0 breast cancer who achieve ycN0 status after neoadjuvant systemic therapy, 3-year survival outcomes after SLNB are comparable to those after ALND, supporting the oncologic safety of axillary surgery deescalation in carefully selected patients within this population.